pepdex
← Back to index
№ 034

Mazdutide

Innovent Biologics' GLP-1 + glucagon dual agonist out of China. Phase 3 data strong, approved in China in 2025 for obesity.

Fat Loss
Evidence: Moderate
Half-life
~4-5 days
Route
Subcutaneous
Cycle
Open-ended, titrate over months
Schedule
Once weekly
In plain English

Mazdutide is a Chinese-developed GLP-1 + glucagon dual agonist — same class as Survodutide and Retatrutide. Approved in China in 2025 for obesity. The glucagon part adds a metabolic-rate bump on top of GLP-1's appetite suppression.

Status & legality
Natty?
Not natty
FDA
Not approved

Not FDA approved. Approved in China (2025) for obesity. Innovent Biologics is running US Phase 3.

Compounding
Investigational

In clinical trials, not yet approved for prescription.

WADA
Not listed
Prescribed

Available by prescription in China. Not yet available in the US.

Who it's for

  • →Users wanting a GLP/glucagon agonist with cleaner side effect profile than Survodutide reports
  • →Followers of Chinese metabolic-drug development

What to expect

  1. Week 1

    Appetite drops. Mild nausea.

  2. Week 4

    First titration step. Modest weight loss.

  3. Week 8

    Cumulative loss tracking similar to Tirzepatide trajectory.

How it works (mechanism)

GLP-1 + glucagon dual agonist developed in China. Same dual-receptor strategy as Survodutide.

Dosing protocol

Start 3 mg weekly. Titrate to 6-9 mg over 4-week steps based on tolerance.

Stacks well with

Standalone is the norm
Some users add MOTS-c during cuts

Side effects

01Nausea
02Constipation or diarrhea
03Mild fatigue
04Slightly elevated heart rate (glucagon effect)

When NOT to use

  • ⚠MTC / MEN-2 history
  • ⚠Pancreatitis history
  • ⚠Pregnancy / nursing

Bloodwork to monitor

  • • Lipid panel
  • • ALT/AST
  • • A1C

Common mistakes

  • • Treating it as freely available — it's only approved in China currently
  • • Titrating too fast
  • • Skipping protein during the cut

Drug & supplement interactions

  • ⚠Insulin and sulfonylureas: dose reduction needed
  • ⚠Glucagon arm: monitor HR
  • ⚠Trial-only outside China — full US interaction profile not yet published

Educational only. User-specific dosing is between you and a qualified provider.

Frequently asked

What is Mazdutide?+
Mazdutide is a Chinese-developed GLP-1 + glucagon dual agonist — same class as Survodutide and Retatrutide. Approved in China in 2025 for obesity. The glucagon part adds a metabolic-rate bump on top of GLP-1's appetite suppression.
Is Mazdutide FDA approved?+
Not FDA approved. Approved in China (2025) for obesity. Innovent Biologics is running US Phase 3.
Is Mazdutide banned by WADA?+
Mazdutide is not currently on the WADA prohibited list.
Are you still natty after taking Mazdutide?+
No. Mazdutide is a performance-enhancing peptide and would disqualify a strict natty claim.
Do doctors prescribe Mazdutide?+
Available by prescription in China. Not yet available in the US.
What's the typical dose of Mazdutide?+
Start 3 mg weekly. Titrate to 6-9 mg over 4-week steps based on tolerance.
What are the side effects of Mazdutide?+
Common side effects include: Nausea; Constipation or diarrhea; Mild fatigue; Slightly elevated heart rate (glucagon effect). Less common effects and full safety details are on the entry page.
How long until Mazdutide starts working?+
Appetite drops. Mild nausea.

More in Fat Loss

№ 008
Tirzepatide

Dual agonist (GLP-1 + GIP). FDA-approved as Mounjaro / Zepbound. Strong weight loss with cleaner side effect profile than semaglutide.

№ 009
Semaglutide

GLP-1 agonist. The original wave. Sold as Ozempic / Wegovy.

№ 003
Retatrutide

Triple agonist (GLP-1 + GIP + glucagon) from Eli Lilly. In trials it outperforms Tirzepatide for weight loss.

№ 058
Liraglutide (Saxenda / Victoza)

Daily GLP-1 receptor agonist. FDA-approved 2010 (Victoza, T2D) and 2014 (Saxenda, obesity). The first wave of modern GLP-1 weight-loss therapy and direct predecessor to Semaglutide.